TAF6L

Across TCGA pan-cancer cohorts, TAF6L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TAF6L data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TAF6L mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TAF6L expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where TAF6L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.882	0.617	.010	11	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
LUAD	OS	Quartile	All	0.956	0.781	.029	5	view →
HNSC	OS	Median	All	1.000	0.959	.023	2	view →
PDAC	DFS	Quartile	All	0.538	0.834	.036	1	view →
GBM	OS	Tertile	All	0.528	0.293	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TAF6L–CCRCC (OS)

Open the CCRCC breakdown →